Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD

36.19  +0.04 (+0.11%)

After market: 36.19 0 (0%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to EXEL. EXEL was compared to 568 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues. EXEL is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make EXEL a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

EXEL had positive earnings in the past year.
In the past year EXEL had a positive cash flow from operations.
Each year in the past 5 years EXEL has been profitable.
In the past 5 years EXEL always reported a positive cash flow from operatings.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

The Return On Assets of EXEL (17.68%) is better than 97.71% of its industry peers.
Looking at the Return On Equity, with a value of 23.23%, EXEL belongs to the top of the industry, outperforming 97.71% of the companies in the same industry.
EXEL has a Return On Invested Capital of 21.31%. This is amongst the best in the industry. EXEL outperforms 98.77% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is below the industry average of 14.25%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(21.31%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.68%
ROE 23.23%
ROIC 21.31%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

With an excellent Profit Margin value of 24.04%, EXEL belongs to the best of the industry, outperforming 97.01% of the companies in the same industry.
EXEL's Profit Margin has declined in the last couple of years.
EXEL has a Operating Margin of 31.81%. This is amongst the best in the industry. EXEL outperforms 98.24% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
The Gross Margin of EXEL (96.49%) is better than 95.25% of its industry peers.
EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.81%
PM (TTM) 24.04%
GM 96.49%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
The number of shares outstanding for EXEL has been reduced compared to 1 year ago.
EXEL has less shares outstanding than it did 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

EXEL has an Altman-Z score of 10.53. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of EXEL (10.53) is better than 89.26% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 10.53
ROIC/WACC2.06
WACC10.33%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 3.63 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio (3.63) which is in line with its industry peers.
A Quick Ratio of 3.58 indicates that EXEL has no problem at all paying its short term obligations.
With a Quick ratio value of 3.58, EXEL perfoms like the industry average, outperforming 44.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 3.58
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 189.06%, which is quite impressive.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 18.50% in the last year.
EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.51% yearly.
EPS 1Y (TTM)189.06%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%77.78%
Revenue 1Y (TTM)18.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%18.16%

3.2 Future

EXEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.65% yearly.
The Revenue is expected to grow by 10.95% on average over the next years. This is quite good.
EPS Next Y13.12%
EPS Next 2Y15.15%
EPS Next 3Y20.67%
EPS Next 5Y26.65%
Revenue Next Year3.94%
Revenue Next 2Y7.32%
Revenue Next 3Y9.63%
Revenue Next 5Y10.95%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 19.56 indicates a rather expensive valuation of EXEL.
EXEL's Price/Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.95% of the companies in the same industry.
When comparing the Price/Earnings ratio of EXEL to the average of the S&P500 Index (28.29), we can say EXEL is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 17.29, the valuation of EXEL can be described as rather expensive.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 94.54% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.08, EXEL is valued at the same level.
Industry RankSector Rank
PE 19.56
Fwd PE 17.29
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

EXEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.48% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, EXEL is valued cheaper than 96.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.08
EV/EBITDA 11.3
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

EXEL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
EXEL's earnings are expected to grow with 20.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.49
PEG (5Y)1.55
EPS Next 2Y15.15%
EPS Next 3Y20.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (4/17/2025, 8:16:03 PM)

After market: 36.19 0 (0%)

36.19

+0.04 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)04-28 2025-04-28/amc
Inst Owners91.92%
Inst Owner Change0%
Ins Owners1.78%
Ins Owner Change15.49%
Market Cap10.13B
Analysts75.56
Price Target37.94 (4.84%)
Short Float %4.85%
Short Ratio5.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.01%
Min EPS beat(2)10.66%
Max EPS beat(2)13.37%
EPS beat(4)3
Avg EPS beat(4)38.82%
Min EPS beat(4)-17.73%
Max EPS beat(4)148.98%
EPS beat(8)5
Avg EPS beat(8)14.06%
EPS beat(12)9
Avg EPS beat(12)18.4%
EPS beat(16)11
Avg EPS beat(16)52.58%
Revenue beat(2)1
Avg Revenue beat(2)3.28%
Min Revenue beat(2)-1.38%
Max Revenue beat(2)7.95%
Revenue beat(4)2
Avg Revenue beat(4)7.85%
Min Revenue beat(4)-9.49%
Max Revenue beat(4)34.34%
Revenue beat(8)3
Avg Revenue beat(8)3.15%
Revenue beat(12)5
Avg Revenue beat(12)1.98%
Revenue beat(16)7
Avg Revenue beat(16)4.23%
PT rev (1m)-0.07%
PT rev (3m)12.56%
EPS NQ rev (1m)-2.45%
EPS NQ rev (3m)-35.04%
EPS NY rev (1m)0.76%
EPS NY rev (3m)20.9%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-0.18%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)3.05%
Valuation
Industry RankSector Rank
PE 19.56
Fwd PE 17.29
P/S 4.67
P/FCF 15.08
P/OCF 14.47
P/B 4.51
P/tB 4.65
EV/EBITDA 11.3
EPS(TTM)1.85
EY5.11%
EPS(NY)2.09
Fwd EY5.78%
FCF(TTM)2.4
FCFY6.63%
OCF(TTM)2.5
OCFY6.91%
SpS7.75
BVpS8.02
TBVpS7.79
PEG (NY)1.49
PEG (5Y)1.55
Profitability
Industry RankSector Rank
ROA 17.68%
ROE 23.23%
ROCE 27.12%
ROIC 21.31%
ROICexc 37.84%
ROICexgc 39.6%
OM 31.81%
PM (TTM) 24.04%
GM 96.49%
FCFM 30.96%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score9
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 98.72%
Cap/Sales 1.31%
Interest Coverage 250
Cash Conversion 97.39%
Profit Quality 128.83%
Current Ratio 3.63
Quick Ratio 3.58
Altman-Z 10.53
F-Score9
WACC10.33%
ROIC/WACC2.06
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)189.06%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%77.78%
EPS Next Y13.12%
EPS Next 2Y15.15%
EPS Next 3Y20.67%
EPS Next 5Y26.65%
Revenue 1Y (TTM)18.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%18.16%
Revenue Next Year3.94%
Revenue Next 2Y7.32%
Revenue Next 3Y9.63%
Revenue Next 5Y10.95%
EBIT growth 1Y303.74%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year21.37%
EBIT Next 3Y26.6%
EBIT Next 5Y1.16%
FCF growth 1Y129.31%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y110%
OCF growth 3Y20.43%
OCF growth 5Y5.84%